- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03539822
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)
A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Anwaar Saeed, MD
- Email: asaeed@kumc.edu
Study Contact Backup
- Name: KUCC Navigator
- Phone Number: 913-588-3671
- Email: kucc_navigation@kumc.edu
Study Locations
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- University of Kansas Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Histologically confirmed diagnosis of any of the following:
- Gastric or gastroesophageal junction adenocarcinoma
- Esophageal adenocarcinoma
- Colorectal adenocarcinoma (CRC)
- Hepatocellular carcinoma (HCC)
- Patients should have advanced (stage 4) or locally unresectable (stage III) disease.
- Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Patients must consent to undergo a required screening/baseline biopsy procedure (and potentially another tumor biopsy at time of disease response and progression) for correlative testing.
- Patients with gastric, gastroesophageal, or esophageal adenocarcinoma must show evidence of progression or intolerance to at least one previous standard of care systemic therapy.
- Patients with CRC must show evidence of progression or intolerance to at least 2 previous standard of care systemic therapy. Ras wild type patients should fail epidermal growth factor receptor (EGFR) monoclonal antibody (panitumumab or cetuximab) to be eligible.
- Patients with HCC must must be treatment naive or show evidence of disease progression or intolerance to at least 1 previous standard of care systemic therapy.
- Patients should have known tumor results for microsatellite instability (MSI) or mismatch repair (MMR) proteins. If unknown, analysis will be obtained through local pathology lab using archival tissue if available or the baseline tumor biopsy.
- Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior treatments unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
- Body weight > 66 lbs (30 kg)
- Adequate organ and marrow function.
- Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.
- Women of child-bearing potential and men with partners of child-bearing potential must agree to use the highly effective forms of contraception prior to study entry, for the duration of study participation, and for 180 Days post completion of therapy. Men of child-bearing potential must not donate sperm while on this study and for 180 Days after their last study treatment.
Exclusion Criteria:
- Prior treatment with a Programmed cell death protein 1 (PD1) or (PD-L1) inhibitor, including durvalumab, or anti PD-L2 (HCC and gastric / esophageal cancer patients with prior exposure to these agents are eligible).
- Prior treatment with cabozantinib or other Receptor for hepatocyte growth factor (MET) or Dual MET/ Hepatocyte growth factor (HGF) monoclonal antibodies or MET/HGF tyrosine kinase inhibitors (TKIs), including crizotinib, foretinib, tivantinib, rilotumumab, and onartuzumab.
Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.
- Evidence of tumor invading the GI tract, (Defined as T4 primary tumor in patients with gastric, gastroesophageal and esophageal adenocarcinoma and CRC).
- Gastric or esophageal varices that are untreated or incompletely treated with bleeding or high risk for bleeding. Subjects treated with adequate endoscopic therapy (according to institutional standards) without any episodes of recurrent GI bleeding requiring transfusion or hospitalization for at least 6 months prior to study entry are eligible.
- Evidence of active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.
- Inability to swallow tablets.
- Uncontrollable ascites or pleural effusion.
- Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.
Clinically significant hematuria, hematemesis, or hemoptysis of >0.5 tsp (2.5ml) of red blood, or other history of significant bleeding within 12 weeks.
* Any sign indicative of pulmonary hemorrhage within 3 months.
* Lesions invading any major blood vessels. HCC subjects with lesions invading the hepatic portal vasculature are eligible.
- Any unresolved toxicity CTCAE Grade ≥2 from previous anticancer therapy
- Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug
- Major surgery (eg, Gastrointestinal (GI) surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses.
- History of allogenic organ transplantation.
- Active or prior documented autoimmune or inflammatory disorders
- History of active primary immunodeficiency
- Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus. HCC patients with hepatitis B or C infection are allowed per protocol specific criteria.
- Receipt of live attenuated vaccine within 30 days prior to the first dose.
- Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 millimeter of mercury (mm Hg) systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.
- Stroke, including transient ischemic attack (TIA), myocardial infarction (MI), or other ischemic event, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 6 months before first dose. Participants with a diagnosis of deep venous thrombosis (DVT) within 6 months are allowed if stable, asymptomatic, and treated with Low Molecular Weight Heparin (LMWH) for at least 2 weeks before first dose.
- Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
- Clinically significant disorders that would preclude safe study participation.
History of another primary malignancy except for:
- Malignancy treated with curative intent/ resection and with no known active disease before the first dose of investigational product (IP) and of low potential risk for recurrence.
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
- Adequately treated carcinoma in situ without evidence of disease.
24. Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:
a. Low-dose aspirin for cardioprotection (per local applicable guidelines) is permitted.
b. Low-dose (prophylactic) low molecular weight heparins (LMWH) are permitted. c. Anticoagulation with therapeutic doses of LMWH is allowed in subjects with no known brain metastases, clinically significant hemorrhage, or complications from a thromboembolic event on the anticoagulation regimen (subjects with HCC must also have a screening platelet count >100,000/μl), and who have been on a stable dose of LMWH for at least 1 week before first dose.
25. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cabozantinib plus Durvalumab (Gastric & esophageal cancer cohort)
Cabozantinib
Durvalumab *Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle |
by mouth
Other Names:
infusion
Other Names:
|
Experimental: Cabozantinib plus Durvalumab (Colorectal cancer cohort)
Cabozantinib
Durvalumab *Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle |
by mouth
Other Names:
infusion
Other Names:
|
Experimental: Cabozantinib plus Durvalumab (Hepatocellular carcinoma cohort)
Cabozantinib
Durvalumab *Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle |
by mouth
Other Names:
infusion
Other Names:
|
Experimental: Cabozantinib plus Durvalumab plus Tremelimumab (Hepatocellular carcinoma cohort)
Cabozantinib
Durvalumab *Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle Tremelimumab *Single dose of 300mg intavenous (IV) infusion on day 1 of cycle 1 |
by mouth
Other Names:
infusion
Other Names:
infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I- Maximum Tolerated Dose (MTD)
Time Frame: 9 months
|
Defined as the highest dose studied for which the observed incidence of dose limiting toxicities (DLT) is less than 33%.
Determined per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
9 months
|
Phase II- Overall Response Rate (ORR)
Time Frame: Every 8 weeks for 12 months
|
Defined as the proportion of participants best response to treatment.
|
Every 8 weeks for 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with adverse events (AEs).
Time Frame: 18 months
|
Determined per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
18 months
|
Overall Benefit Rate (OBR)
Time Frame: 18 months
|
Defined as the proportion of patients with overall benefit to therapy.
Overall benefit is defined as the best response recorded, (including complete Response (CR), Partial Response (PR), and Stable Disease (SD)), from the start of the treatment until the end of treatment.
Determined per Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
|
18 months
|
Progression Free Survival (PFS)
Time Frame: 24 months
|
Defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first.
Determined per Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
|
24 months
|
Overall Survival (OS)
Time Frame: 24 months
|
Defined as the time from the start of treatment until death due to any cause.
Determined per Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anwaar Saeed, MD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma, Hepatocellular
- Adenocarcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Durvalumab
- Tremelimumab
- Immune Checkpoint Inhibitors
- Tyrosine Protein Kinase Inhibitors
Other Study ID Numbers
- 22-192
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on Cabozantinib
-
University of BolognaIpsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaboratorsUnknownNon Small Cell Lung CancerItaly
-
ExelixisCompletedCancer | NSCLC | Solid TumorsJapan
-
University of WashingtonNational Cancer Institute (NCI); Prostate Cancer FoundationTerminatedRecurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
Jennifer KingExelixisRecruitingOvarian Germ Cell Tumor | Seminoma | Germ Cell Tumor | Non-seminomatous Germ Cell TumorUnited States
-
Memorial Sloan Kettering Cancer CenterExelixisRecruiting
-
University of Michigan Rogel Cancer CenterExelixisActive, not recruitingAdvanced Adult Hepatocellular CarcinomaUnited States
-
Thomas Jefferson UniversityActive, not recruitingDifferentiated Thyroid Cancer (DTC) | Poorly Differentiated Thyroid CancerUnited States
-
Fondazione Ricerca TraslazionaleUnknownNon-Small Cell Lung CancerItaly
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Karsten GavenisRecruitingNeuroendocrine Tumors | Neuroendocrine CarcinomaGermany, Austria